Trial Profile
A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of UB-221 as an Add-on Therapy in Patients With Chronic Spontaneous Urticaria
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Aug 2022
Price :
$35
*
At a glance
- Drugs UB 221 (Primary)
- Indications Urticaria
- Focus Adverse reactions
- Sponsors United BioPharma
- 05 Aug 2022 According to a United BioPharma media release, results were published in the latest Journal of Clinical Investigation (JCI).
- 05 Aug 2022 Results published in United BioPharma Media Release
- 12 Apr 2021 Status changed from recruiting to completed.